ADC Therapeutics Doses First Patient in Phase Ib Clinical

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
38
ADC Therapeutics Doses First Patient in Phase Ib Clinical Trial of ADCT-301 in Patients with Advanced Solid Tumors

LAUSANNE, Switzerland, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase Ib clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-301 (camidanlumab tesirine) in patients with selected solid tumors that are locally advanced or metastatic. 

ADCT-301 is already being evaluated in relapsed and refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). At the 2018 American Society of Hematology (ASH) Annual Meeting, ADC Therapeutics presented interim data on 113 patients dosed in its Phase Ia/Ib clinical trial in lymphoma. In HL patients with a median of five prior lines of therapy and no other approved therapy options, the overall response rate was 86.5 percent, including a 43 percent complete response rate, at the dose being considered for a pivotal Phase II clinical trial that the Company anticipates initiating in 2019.

Jay Feingold, MD, PhD, Chief Medical Officer and Senior Vice President of Clinical Development at ADC Therapeutics, said, “We continue to be very encouraged by the anti-tumor activity of ADCT-301 in Hodgkin lymphoma and non-Hodgkin lymphoma. In addition, based on the immune-oncology potential ADCT-301 has demonstrated in preclinical studies, we are excited to be starting this clinical trial for ADCT-301 in solid tumors to see if we can make an impact and improve patient outcomes in multiple difficult-to-treat solid tumor cancers.”

ADCT-301 in Solid Tumors

At the Society for Immunotherapy of Cancer’s (SITC) 33 rd Annual Meeting, ADC Therapeutics presented preclinical data showing that an engineered version of ADCT-301 demonstrated highly potent anti-tumor activity, both as a monotherapy and in combination with a checkpoint inhibitor, in multiple solid tumor models with infiltrating CD25-positive regulatory T cells (Tregs).

Patrick van Berkel, PhD, Senior Vice President of Research and Development at ADC Therapeutics, said, “ADCT-301 targets CD25, which is expressed on Tregs that infiltrate the local tumor environment. In preclinical models, a single dose of the CD25-targeted ADC induced strong and durable anti-tumor activity against established CD25-negative solid tumors with infiltrating Tregs both as a monotherapy and in combination with a checkpoint inhibitor. Moreover, re-challenged mice did not develop new tumors indicating the CD25-targeted ADC was able to induce tumor-specific protective immunity.”

The Phase Ib trial of ADCT-301 in patients with advanced solid tumors has both dose escalation and cohort expansion parts. The dose escalation part is designed to establish a safe and tolerated dose and dosing schedule of ADCT-301 in these patients. The identified dose and dosing schedule will be studied in the dose expansion part. Approximately 50 patients will be enrolled in the trial.

For more information about this Phase Ib clinical trial in solid tumors, please visit www.clinicaltrials.gov (identifier NCT03621982).

About ADCT-301

ADCT-301 (camidanlumab tesirine) is an antibody drug conjugate (ADC) composed of a monoclonal antibody that binds to CD25 (HuMax®-TAC, licensed from Genmab A/S), conjugated to a pyrrolobenzodiazepine (PBD) dimer toxin. Once bound to a CD25-expresing cell, ADCT-301 is internalized into the cell where enzymes release the PBD-based warhead. The intra-tumor release of its PBD warhead may cause bystander killing of neighboring tumor cells. In addition, the PBD warhead will trigger immunogenic cell death, which in turn will strengthen the immune response against tumor cells.  In addition to the Phase Ib clinical trial in solid tumors, ADCT-301 is being evaluated in ongoing Phase Ia/Ib clinical trials in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma ( NCT02432235 ).

About ADC Therapeutics

ADC Therapeutics SA is an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs) targeting major hematological malignancies and solid tumors. The Company’s ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads via a chemical linker. The Company has five PBD-based ADCs in ongoing clinical trials in the USA and Europe, and a deep pipeline of other preclinical ADCs in development. ADC Therapeutics has world-class partners, including AstraZeneca and its global biologics research and development arm, MedImmune. The Company is based in Lausanne (Biopôle), Switzerland and has operations in London, San Francisco and New Jersey. For more information, visit www.adctherapeutics.com .

Investors Contact     EU Media Contact     USA Media Contact
Dr. Chris Martin     Alexandre Müller     Tony Plohoros
Chief Executive Officer     Dynamics Group     6 Degrees
Chris.martin@adctherapeutics.com     amu@dynamicsgroup.ch     tplohoros@6degreespr.com
Tel.: +41 (0) 21 653 0200     Tel: +41 (0) 43 268 3231     Tel.: +1 908-591-2839
             

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 21

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Surfcomber Uses Art Week to Deepen Its Guest Appeal

Updated Category News Views 39

Miami Art Week can turn every hotel lobby into a billboard, but Surfcomber is at least trying to make its walls do some actual work. Kimpton Surfcomber Hotel is spreading local artists, participatory events, food, cocktails and retail across the property rather than hanging a few paintings and calling it culture. For a South Beach hotel with 200 feet of oceanfront, that...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 60

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
AV Access iDock B12 Chases the Growing Two-PC Desk Boom

Updated Category News Views 149

Cable spaghetti has become an oddly durable tax on anyone running a work laptop beside a gaming tower, and AV Access is taking a proper swing at it with the iDock B12. This is not some mystical new category; it is a KVM switch and docking station mashed together for a desk that has to serve two masters. Still, the company has aimed at the parts that usually get sacrificed...

Continue Reading
UnitedHealth’s CMS Audit Shock Puts Disclosures Under Lens

Updated Category News Views 123

Medicare Advantage's audit bill just landed with a nasty thud. UnitedHealth Group shares fell more than 10% on November 18 after the Centers for Medicare & Medicaid Services proposed new anti-fraud, audit, and repayment rules for the program. For holders of NYSE:UNH, this was not some sleepy policy memo buried in a federal filing cabinet. It was a hard reminder that...

Continue Reading
Botanica’s Illuminations Carries More Than Holiday Glow

Updated Category News Views 106

Two million lights are doing more than brightening up a few winter evenings in Wichita. Illuminations at Botanica returns from November 23, 2026, through January 2, 2027, and the pleasant part of this story is that the spectacle has a practical backbone: it is Botanica’s largest fundraiser. For a garden nonprofit, that matters a whole lot more than another shiny...

Continue Reading
Sports Leagues Confront Youth Gambling's Hard Truth

Updated Category News Views 7

A stadium-sized advertising machine cannot pretend kids are not watching. That is the uncomfortable backdrop to the National Council on Problem Gambling's November 10 youth gambling prevention summit, where representatives from the NFL, MLB, NBA and PGA Tour met at the NFL's New York offices. Good that they showed up. Frankly, with gambling stitched into so much sports...

Continue Reading
Boston Scientific Loads Debt Cannon for Penumbra Deal

Updated Category News Views 128

A Very Large Financing Cart Rolled Out Boston Scientific just put an enormous stack of paper into the market, and nobody should mistake this for routine housekeeping. The company priced $3.0 billion of U.S. dollar senior notes and €4.25 billion of euro notes, with proceeds earmarked chiefly for the cash portion of its proposed Penumbra acquisition, alongside cash on...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 135

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
SeoulTech's Liver Chip Makes Toxicity Testing Practical

Updated Category News Views 32

A Lab Tool Finally Built for the Messy Part Thousands of everyday chemicals are floating around commerce with thin toxicity records, and that is a lousy way to run a modern economy. Seoul National University of Science and Technology researchers have put forward a modular liver-on-a-chip platform aimed squarely at that gap: making environmental chemical testing more...

Continue Reading

Top 5 Most Recently Viewed Articles

InfoSync Services Partners with CogentHub for Strategic Growth

Updated Category News Views 732

InfoSync Services Partners with CogentHub for Strategic Growth In a significant move for the professional services landscape, InfoSync Services, a renowned provider of outsourced solutions, has been sold from Staple Street Capital to CogentHub. This transition marks an exciting chapter not only for InfoSync but also for its clients and the wider market. Understanding...

Continue Reading
Call for Major Economic Stimulus in China: $1.4 Trillion Boost

Updated Category News Views 211

China's Proposal for Economic Stimulus Amid global economic strains, a well-regarded former central bank adviser has put forth a notable idea: China could consider issuing ultra-long-term treasury bonds, which might generate an impressive 10 trillion yuan (around $1.4 trillion) in stimulus. This proactive suggestion was shared at the China Macroeconomy Forum and...

Continue Reading
Cavitation Technologies: Strategic Growth Plans Ahead of 2025

Updated Category News Views 261

Strategic Growth Plans for Cavitation Technologies, Inc. Cavitation Technologies, Inc. (OTCQB: CVAT) is committed to advancing its innovative capabilities in the fields of water treatment and beverage technology. As the company looks toward the future, it aims to capitalize on existing technologies while exploring new partnerships that will enhance its operations....

Continue Reading
How a $1000 Investment in Insulet Transformed Over 15 Years

Updated Category News Views 141

How Insulet Has Thrived Over the Years Insulet (NASDAQ:PODD) has shown remarkable performance, exceeding market expectations over a 15-year span with an impressive annualized return of 23.78%. This is a testament to strong financial growth, significantly outperforming many competitors. The Incredible Growth of a $1000 Investment Consider this: imagine if you invested...

Continue Reading
Synovus Executives Set to Discuss Insights at Conference

Updated Category News Views 70

Synovus Financial Corp. at the BancAnalysts Association Conference Synovus Financial Corp. (NYSE: SNV) is preparing for its participation in a highly anticipated conference that gathers financial experts and analysts. The event will feature a fireside chat with the company’s leadership, including Chairman, CEO, and President Kevin Blair along with Executive Vice...

Continue Reading